Comparative Study Sheds New Light on Ulcerative Colitis
In April 2025, guselkumab, a human monoclonal antibody targeting the interleukin-23 (IL-23) pathway, received approval for the treatment of adults ...
In April 2025, guselkumab, a human monoclonal antibody targeting the interleukin-23 (IL-23) pathway, received approval for the treatment of adults ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine